Clinical trials: Drug Half Life
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia
Self Help Program for Hypnotics Withdrawal in Insomniac Patients
Persistent insomnia has a high prevalence in French general population affecting between 15.8 % and 19 % of adults. In France, the disease is mainly managed by general practitioners (GP) who usually proposed intermediate…
- Trial name
- PROPERSOM (NCT02720458)
- Testing
- Standardized gradual hypnotic taper, Short-term simple self-help program
- Where
- 6 sites in France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Bordeaux
Severe Haemophilia B
Dosage and PD Study of Eftrenonacog-alfa
The purpose of this study is to evaluate the performance of different methods for measuring factor IX activity levels in haemophilia B patients treated with eftrenonacog-alfa and assess its pharmacodynamics (PD) in a real-life…
- Trial name
- BIOPAL (NCT04590950)
- Testing
- Non interventional study
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Placebo Effect, Drug Half Life
The Placebo Effect May Involve Modulating Drug Bioavailability
The total effect of a medication is the sum of its drug effect, placebo effect (meaning response of placebo), and their interaction.
- Conditions
- Placebo Effect, Drug Half Life, Pharmacokinetics
- Trial name
- NCT01501747
- Testing
- Caffeine, paracetamol, cephalexin, or ibuprofen
- Where
- Saudi Arabia
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- King Faisal Specialist Hospital & Research Center
Schizophrenia, Schizoaffective Disorder
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
Ziprasidone is recommended to be dosed twice daily for the treatment of schizophrenia, based on peripheral pharmacokinetics and a knowledge of its half life in plasma level (5-10 hours).
- Trial name
- NCT00818298
- Testing
- ziprazidone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Advanced Nasopharyngeal Carcinoma
New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow earlier and more detection of drug response in advanced NPC than RECIST method, in patients with previously untreated advanced NPC who…
- Trial name
- NCT01365208
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- Chinese University of Hong Kong